HALOG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALOG (HALOG).
Halcinonide is a synthetic corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokine production.
| Metabolism | Hepatic via CYP3A4; excreted renally |
| Excretion | Primarily renal (≈65% as metabolites, <1% unchanged), with biliary/fecal elimination (≈35%, including enterohepatic circulation). |
| Half-life | Terminal elimination half-life: 48–72 hours. Prolonged half-life allows once-daily to twice-weekly dosing; requires careful tapering to avoid adrenal suppression. |
| Protein binding | ≥99% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | Vd: 0.5–1.4 L/kg (approximate range for topical corticosteroids; indicates extensive tissue distribution and high lipid solubility). |
| Bioavailability | Topical: absorption varies from <1% (intact skin) to up to 36% (occluded or damaged skin). Oral: ≈100% (not clinically used). |
| Onset of Action | Topical: clinical improvement seen within 1–2 weeks of regular application. |
| Duration of Action | Duration of action after topical application: effects persist for days to weeks due to reservoir effect in stratum corneum; systemic effects (adrenal suppression) may last weeks after discontinuation of prolonged therapy. |
0.01-0.025% cream or ointment applied topically to affected area twice daily for 2-4 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical use. Systemic absorption minimal; no GFR-based modifications. |
| Liver impairment | No dose adjustment required for topical use. Excessive use in severe hepatic impairment may increase systemic absorption; use with caution. |
| Pediatric use | Apply a thin film of 0.01% cream or ointment topically twice daily for 2 weeks in children 2 years and older. Not recommended for infants under 2 years due to increased systemic absorption risk. |
| Geriatric use | Use lowest effective dose (0.01% strength) for shortest duration due to thinner skin and increased systemic absorption risk. Avoid prolonged use in intertriginous areas. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HALOG (HALOG).
| Breastfeeding | Excreted in breast milk. M/P ratio unknown. Use caution; avoid high doses and prolonged application to prevent infant adrenal suppression. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Animal studies show cleft palate and delayed ossification; human data limited. Second/third trimester: Prolonged use may cause fetal adrenal suppression, intrauterine growth restriction. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to halcinonide or any component of the formulation","Untreated bacterial, fungal, viral (e.g., herpes simplex, vaccinia, varicella) infections"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Local adverse reactions include burning, itching, irritation, dryness, folliculitis, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria"] |
Loading safety data…
| Monitor maternal blood pressure, blood glucose, electrolytes with prolonged use. Fetal ultrasound for growth restriction and adrenal suppression if used chronically. |
| Fertility Effects | No human studies. In animals, high doses may impair fertility; reversible upon discontinuation. |